Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.23.00617 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Soumyajit Roy und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Rush University Medical Center, Chicago, IL. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. MATERIALS AND METHODS Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained. Surrogate candidacy was assessed using the Prentice criteria (including landmark analyses) and the two-stage meta-analytic approach (estimating Kendall's tau and the R 2 ). Biochemical recurrence-free survival (BCRFS, time from random assignment to BCR or any death) and time to BCR (TTBCR, time from random assignment to BCR or cancer-specific deaths censoring for noncancer-related deaths) were assessed. RESULTS Overall, 10,741 patients were included. Dose escalation, addition of short-term ADT, and prolongation of ADT duration significantly improved BCR (hazard ratio [HR], 0.71 [95% CI, 0.63 to 0.79]; HR, 0.53 [95% CI, 0.48 to 0.59]; and HR, 0.54 [95% CI, 0.48 to 0.61], respectively). Adding short-term ADT (HR, 0.91 [95% CI, 0.84 to 0.99]) and prolonging ADT (HR, 0.86 [95% CI, 0.78 to 0.94]) significantly improved OS, whereas dose escalation did not (HR, 0.98 [95% CI, 0.87 to 1.11]). BCR at 48 months was associated with inferior OS in all three groups (HR, 2.46 [95% CI, 2.08 to 2.92]; HR, 1.51 [95% CI, 1.35 to 1.70]; and HR, 2.31 [95% CI, 2.04 to 2.61], respectively). However, after adjusting for BCR at 48 months, there was no significant treatment effect on OS (HR, 1.10 [95% CI, 0.96 to 1.27]; HR, 0.96 [95% CI, 0.87 to 1.06] and 1.00 [95% CI, 0.90 to 1.12], respectively). The patient-level correlation (Kendall's tau) for BCRFS and OS ranged between 0.59 and 0.69, and that for TTBCR and OS ranged between 0.23 and 0.41. The R 2 values for trial-level correlation of the treatment effect on BCRFS and TTBCR with that on OS were 0.563 and 0.160, respectively. CONCLUSION BCRFS and TTBCR are prognostic but failed to satisfy all surrogacy criteria. Strength of correlation was greater when noncancer-related deaths were considered events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Rush University Medical Center, Chicago, IL.
- Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.
- Department of Radiation Oncology, Washington University, St Louis, MO.
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA.
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI.
ORCID-Profile: Soumyajit Roy, Jeff M Michalski, Felix Y Feng, Jason A Efstathiou, Michel Bolla, Philippe Maingon, Wee Loon Ong, Matthew R Sydes, David P Dearnaley, Alison C Tree, Abdenour Nabid, Luca Incrocci, Wilma D Heemsbergen, Floris J Pos, Almudena Zapatero, Ana Alvarez, Robert E Reiter, Matthew B Rettig, Michael L Steinberg, Luca F Valle, T Martin Ma, Matthew J Farrell, Beth K Neilsen, Jesus E Juarez, Jie Deng, Angela Y Jia, Nicholas G Zaorsky, Yilun Sun, Daniel Spratt, Amar U Kishan
Förderung
- NCI NIH HHS
Zitieren
APA
Roy, S., Romero, T., Michalski, J. M., Feng, F. Y., Efstathiou, J. A., Lawton, C. A. F., Bolla, M., Maingon, P., de Reijke, T., Joseph, D., Ong, W. L., Sydes, M. R., Dearnaley, D. P., Tree, A. C., Carrier, N., Nabid, A., Souhami, L., Incrocci, L., Heemsbergen, W. D., …, & Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators (2023). Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00617
Vancouver
Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, et al. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.00617
BibTeX
@article{Roy2023,
author = {Roy, Soumyajit and Romero, Tahmineh and Michalski, Jeff M and Feng, Felix Y and Efstathiou, Jason A and Lawton, Colleen A F and Bolla, Michel and Maingon, Philippe and de Reijke, Theo and Joseph, David and Ong, Wee Loon and Sydes, Matthew R and Dearnaley, David P and Tree, Alison C and Carrier, Nathalie and Nabid, Abdenour and Souhami, Luis and Incrocci, Luca and Heemsbergen, Wilma D and Pos, Floris J and Zapatero, Almudena and Guerrero, Araceli and Alvarez, Ana and San-Segundo, Carmen Gonzalez and Maldonado, Xavier and Reiter, Robert E and Rettig, Matthew B and Nickols, Nicholas G and Steinberg, Michael L and Valle, Luca F and Ma, T Martin and Farrell, Matthew J and Neilsen, Beth K and Juarez, Jesus E and Deng, Jie and Vangala, Sitaram and Avril, Norbert and Jia, Angela Y and Zaorsky, Nicholas G and Sun, Yilun and Spratt, Daniel and Kishan, Amar U and Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators},
title = {Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.23.00617}
}
EUVIMED